HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

The Indian market is expected to trade higher on January 15, supported by positive global cues. Nifty futures gained 0.51% on ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

Biocon jumped 4.03% to Rs 375.40 after the company said that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins facilities in Johor Bahru, Malaysia as voluntary ...

Motilal Oswal (MOSL) has reiterated its "Buy" rating on HCL Technologies, setting a target price of Rs 2,400, which implies a ...

BRIDGEWATER, N.J., and BENGALURU, India, Jan. 9, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523 ...